Opening Asia for Russia

India plans to sign a contract with Johnson & Johnson for the production of a vaccine

11.02.2021 43 просмотров

Johnson & Johnson is preparing to produce a coronavirus vaccine in India.


The Indian company Biological E Lt (“Biological I”) intends to sign a contract with the American corporation Johnson & Johnson (Johnson & Johnson) to produce up to 600 million doses of its coronavirus vaccines at its facilities annually. The Times of India reported on Wednesday.

“We aim to sign a contract with Johnson & Johnson to produce up to 600 million doses of the corporation's COVID-19 vaccines in addition to our own drug from of coronavirus, the production volume of which will be approximately 1 billion doses, ”the publication quotes the words of the head of Biological E Mahima Date.

The time for signing the contract has not been finalized. It is also not yet known exactly when the so-called interim safety and immunogenicity study of the Johnson & Johnson vaccine will take place in India, which is mandatory for all foreign-developed medicines.

According to representatives of the Ministry of Health of the Republic, Johnson & Johnson is ready to manufacture its vaccine in India. It was developed by the Baylor College of Medicine in Houston and the American company Danavax Technologies (Denavax Technologies).

Vaccination campaign in India

The Indian Ministry of Health believes that the release of the drug Johnson & Johnson Corporation is needed to ramp up the nationwide, "world's largest" coronavirus vaccination campaign. It began on January 16, and so far more than 6.6 million people have received vaccinations in the country. It is planned that at the first stage, about 30 million people will receive the vaccine - 10 million health workers and 20 million employees at risk - police officers, military personnel, employees of civil defense departments. Then people over 50 years of age and people under the age of 50 years with concomitant diseases will be vaccinated (about 270 million people in total).

India plans to vaccinate about 300 million people against coronavirus by July.

At the first stage, vaccinations are made with two vaccines - the drug Covishield (Covishild), developed by the British-Swedish company AstraZeneca (AstraZeneca) and Oxford University, and Covaxin (Covaxin) by the Indian company Bharat Biotech (Bharat biotek). Both vaccines are produced in India. In addition, several more drugs are undergoing clinical trials in the country at various stages, including the Russian vaccine Sputnik V.

Новости партнёров